RPS6 and brain disorder: Disorders within the mTOR and MAPK pathways are characteristic of patients with ASD (e.g., an increase in protein p-EIF4E, rpS6, ERK1–2 in blood) and are an important target in the search for a treatment for this brain disease [68,69].